Kepler Capital Markets reiterated their reduce rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report sent to investors on Thursday morning. Kepler Capital Markets currently has a GBX 1,520 ($19.80) price objective on the stock.
Several other equities analysts also recently issued reports on GSK. UBS AG set a GBX 1,600 ($20.84) price objective on GlaxoSmithKline plc and gave the company a neutral rating in a research report on Thursday, April 27th. Deutsche Bank AG restated a hold rating on shares of GlaxoSmithKline plc in a research report on Wednesday, July 19th. J P Morgan Chase & Co restated a neutral rating on shares of GlaxoSmithKline plc in a research report on Monday. Shore Capital restated a hold rating on shares of GlaxoSmithKline plc in a research report on Thursday, July 20th. Finally, Bryan, Garnier & Co restated a buy rating and set a GBX 1,750 ($22.80) target price on shares of GlaxoSmithKline plc in a research report on Thursday, July 20th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of GBX 1,734.73 ($22.60).
Shares of GlaxoSmithKline plc (LON:GSK) traded down 0.82% on Thursday, reaching GBX 1518.50. The company had a trading volume of 9,936,536 shares. GlaxoSmithKline plc has a one year low of GBX 1,446.50 and a one year high of GBX 1,745.56. The firm’s market cap is GBX 74.19 billion. The company has a 50-day moving average price of GBX 1,638.77 and a 200-day moving average price of GBX 1,627.17.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/07/29/glaxosmithkline-plc-longsk-given-reduce-rating-at-kepler-capital-markets.html.
The company also recently declared a dividend, which will be paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th will be issued a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 10th. This represents a dividend yield of 1.23%.
In other news, insider Patrick Vallance purchased 861 shares of the business’s stock in a transaction dated Friday, July 14th. The shares were bought at an average cost of GBX 1,618 ($21.08) per share, for a total transaction of £13,930.98 ($18,148.75). Also, insider Manvinder Singh Banga purchased 2,267 shares of the business’s stock in a transaction dated Wednesday, July 26th. The stock was purchased at an average price of GBX 1,599 ($20.83) per share, for a total transaction of £36,249.33 ($47,224.24). Over the last 90 days, insiders bought 3,150 shares of company stock worth $5,054,075.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.
